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Abstract
This report describes the rationale and design of a study assessing tolvaptan in children with autosomal dominant polycystic
kidney disease (ADPKD). Phase A is a 1-year, randomized, double-blind, placebo-controlled, multicenter trial. Phase B is a 2-
year, open-label extension. The target population is at least 60 children aged 12–17 years, diagnosed by family history and/or
genetic criteria and the presence of ≥ 10 renal cysts, each ≥ 0.5 cm onmagnetic resonance imaging. Subjects will be allocated into
4 groups: females 15–17 years; females 12–14 years; males 15–17 years; and males 12–14 years. Up to 40 subjects aged 4–
11 years may also enroll, provided they meet the entry criteria. Weight-adjusted tolvaptan doses, titrated once to achieve a
tolerated maintenance dose, and matching placebo will be administered twice-daily. Assessments include spot urine osmolality
and specific gravity (co-primary endpoints), height-adjusted total kidney volume, estimated glomerular filtration rate, pharma-
codynamic parameters (urine volume, fluid intake and fluid balance, serum sodium, serum creatinine, free water clearance),
pharmacokinetic parameters, safety (aquaretic adverse events, changes from baseline in creatinine, vital signs, laboratory values
including liver function tests), and generic pediatric quality of life assessments.
Conclusion: This will be the first clinical study to evaluate tolvaptan in pediatric ADPKD.
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What is Known:
• Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder causing the development of cysts that impede kidney function over time
and eventually induce renal failure
• There are few data on the effects of tolvaptan, the only treatment approved for adults to slow disease progression, in pediatric ADPKD patients with
early-stage disease
What is New:
• A phase 3, placebo-controlled study is evaluating tolvaptan over 3 years in children and adolescents with ADPKD
• This study is designed to account for challenges of tolvaptan dosing and outcome assessment specific to the pediatric population
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Abbreviations
ADPKD Autosomal dominant polycystic kidney disease
AEs Adverse events
ALP Alkaline phosphatase
ALT Alanine aminotransferase
AST Aspartate aminotransferase
BT Total bilirubin
CKD Chronic kidney disease
CRISP Consortium for Radiologic Imaging Studies of
Polycystic Kidney Disease
DILI Drug-induced liver injury
eGFR Estimated glomerular filtration rate
ESKD End-stage kidney disease
MRI Magnetic resonance imaging
PD Pharmacodynamics
PK Pharmacokinetics
REPRISE Replicating Evidence of Preserved Renal
Function: an Investigation of Tolvaptan Safety
and Efficacy in ADPKD
TEMPO
3:4
Tolvaptan Efficacy and Safety inManagement of
Autosomal Dominant Polycystic KidneyDisease
and Its Outcomes 3:4
TKV Total kidney volume
ULN Upper limit of normal
Introduction
Autosomal dominant polycystic kidney disease (ADPKD) is
the most common inherited disorder of the kidney [8, 18].
Dysregulation of the primary cilium on renal epithelial cells
causes localized and unregulated expansion of the nephronic
epithelium, resulting in the formation of fluid-filled cysts that
grow and ultimately obstruct nephrons, blood vessels, and
lymphatics [10]. In general, disease progression is inexorable,
with an estimated 45–70% of patients developing end-stage
kidney disease (ESKD) by age 65 years [11]. ADPKD is the
fourth most common cause of ESKD, after diabetes, hyper-
tension, and glomerulonephritis, accounting for 10% of pa-
tients receiving dialysis or kidney transplantation in Europe
[17].
Tolvaptan, an oral selective antagonist of the vasopressin
V2 receptor, is the only medication for ADPKD that has dem-
onstrated beneficial disease-modifying properties in adults.
Phase 3 clinical trials demonstrated the efficacy of tolvaptan
in slowing the decline of kidney function in adults with rela-
tively early-stage ADPKD and high likelihood of rapid dis-
ease progression (the Tolvaptan Efficacy and Safety in
Management of Autosomal Dominant Polycystic Kidney
Disease and Its Outcomes 3:4 [TEMPO 3:4] trial) and those
with more advanced disease (the Replicating Evidence of
Preserved Renal Function: an Investigation of Tolvaptan
Safety and Efficacy in ADPKD [REPRISE] trial) [19, 21].
The Consortium for Radiologic Imaging Studies of
Polycystic Kidney Disease (CRISP) established that kidney
enlargement is a continuous process in ADPKD, with cysts
expanding in young patients years or even decades before renal
damage becomes apparent [1, 9, 14]. Cysts steadily develop
and grow in children with ADPKD while kidney function re-
mains normal, even as these patients manifest early symptoms
such as nocturnal hypertension [12]. It is therefore reasonable to
hypothesize that treatment with a disease-modifying agent like
tolvaptan prior to adulthood might have beneficial effects on
long-term outcomes. Of relevance, a recent case study found
that treatment with tolvaptan resolved hyponatremia and
prevented kidney enlargement in a female infant with con-
firmed ADPKD [7]. To further address the potential role of
tolvaptan in pediatric disease, the current report describes the
rationale and design of the first study to assess the pharmaco-
dynamics (PD), pharmacokinetics (PK), safety, and efficacy of
tolvaptan in children and adolescents with ADPKD. The study
design was developed, in discussions with regulatory authori-
ties, to provide initial data on the use of tolvaptan in children
with ADPKD at high risk of progression, with focus on safety
of use, appropriate dosing, and pharmacodynamic activity.
Methods
Subjects
The target population will consist of at least 60 male and
female subjects aged 12–17 years who have a diagnosis of
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ADPKD, as defined by the presence of renal cysts, ADPKD
family history, and/or genetic criteria. To be eligible, subjects
must have ≥ 10 renal cysts, each measuring ≥ 0.5 cm on mag-
netic resonance imaging (MRI) inspection. Prospective sub-
jects who are MRI naive should have an ultrasound to confirm
the presence of ≥ 4 cysts, each ≥ 1 cm in size, prior to
receiving a trial-specific MRI inspection. Subjects aged 4–
11 years will also be allowed to enter the study during the
recruitment period for the target population, provided they
meet entry criteria. For the younger group, MRI assessment
is not performed; accordingly, the detection of ≥ 4 renal cysts
on ultrasound, each ≥ 1 cm in size, suffices to confirm cyst
Table 1 Eligibility requirements
Inclusion criteria
• Male and female subjects aged 4 to 17 years (inclusive) with a diagnosis of ADPKD as defined by the presence of family history and/or genetic
criteria AND who have at least 10 renal cysts, each of which measures at least 0.5 cm, confirmed upon MRI inspection; subjects under the age of
12 years must have at least 4 cysts that are at least 1 cm in size, confirmed by ultrasound
• Weight ≥ 20 kg
• eGFR ≥ 60 mL/min/1.73 m2 within 31 days prior to randomization (using the Schwartz formula, eGFR = 0.413 × height [cm]/serum creatinine
mg/dL [15])
• Independent in toileting
• Trial-specific written informed consent obtained from a parent/guardian or legally acceptable representative, as applicable for local laws, at screening,
prior to the initiation of any protocol-required procedures. In addition, the subject must provide age-appropriate informed assent at screening and
must be able to understand that he or she can withdraw from the trial at any time
• Ability to swallow a tableta
•Ability to commit to remain fully abstinent (periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] or withdrawal are
not acceptable methods of contraception) or use two approved methods of birth control during the trial and for 30 days following the last dose of
study drug for sexually active females of childbearing potential
Exclusion criteria
• Females who are breastfeeding and/or who have a positive pregnancy test result prior to receiving study drug
• Liver function tests, including AST and ALT, ≥ 1.5 × upper limit of normal
• Nocturnal enuresis
• Need for chronic diuretic use
• Subjects with advanced diabetes (e.g., glycosylated hemoglobin > 7.5% and/or glycosuria by dipstick, significant proteinuria, retinopathy), evidence
of additional significant renal disease(s) (i.e., currently active glomerular nephritides), renal cancer, single kidney, or recent (within last 6 months)
renal surgery or acute kidney injury
• Subjects who have known clinically significant allergic reactions to chemicals with structure similar to tolvaptan (i.e., benzazepines): benzazepril,
conivaptan, fenoldopam mesylate, or mirtazapine
• Subjects having disorders in thirst recognition or inability to access fluids
• Subjects who have bladder dysfunction and/or difficulty voiding
• Subjects with critical electrolyte imbalances, as determined by the investigator
• Subjects with or at risk of significant hypovolemia, as determined by investigator
• Subjects with a history of substance abuse (within the last 6 months)
• Subjects 12 years of age and older having contraindications to, or interference with, MRI assessments (e.g., ferro-magnetic prostheses, aneurysm
clips, severe claustrophobia)
• Subjects taking a vasopressin agonist (e.g., desmopressin)
• Subjects with a history of persistent noncompliance with antihypertensive or other important medical therapy
• Subjects taking medications or having concomitant illnesses likely to confound endpoint assessments, including taking approved (i.e., marketed)
therapies for the purpose of affecting polycystic kidney disease cysts such as tolvaptan, vasopressin antagonists, anti-sense RNA therapies,
rapamycin, sirolimus, everolimus, or somatostatin analogs (i.e., octreotide, sandostatin)
• Has any medical condition that, in the opinion of the investigator, could interfere with evaluation of the trial objectives or safety of the subjects
• Is deemed unsuitable for trial participation in the opinion of the investigator
• Subjects who received any investigational agent in a clinical trial within 30 days prior to screening
• Subjects who have a known lactose intolerance
• Subjects who have had cyst reduction surgery within 6 weeks of the screening visit
ADPKD autosomal dominant polycystic kidney disease, ALT alanine aminotransferase, AST aspartate aminotransferase, eGFR estimated glomerular
filtration rate, MRI magnetic resonance imaging, RNA ribonucleic acid
aMust also meet health authority/ethics committee age restrictions on tablet use (if applicable)
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presence. (Full inclusion/exclusion criteria in Table 1) While
the required enrollment is 60 subjects aged 12–17 years, it is
expected that the trial may also enroll approximately 40 sub-
jects aged 4–11 years, for a total sample size of approximately
100 subjects.
Study design
This is an ongoing, phase 3b, two-part study (EudraCT num-
ber: 2016-000187-42; ClinicalTrials.gov identifier:
NCT02964273) [3, 5]. Enrollment started in September
2016, and the estimated primary completion date is
December 2019, with study completion anticipated in
December 2021 [3]. Twenty study sites located in Belgium,
Germany, Italy, and the UK are participating. The trial is being
conducted in compliance with FDA regulations, International
Conference on Harmonization Good Clinical Practice
Guideline (E6), international ethical principles derived from
the Declaration of Helsinki, Council for International
Organizations of Medical Science guidelines, and applicable
local laws and regulations. Age-appropriate assent documents
were created.
Phase A Phase A is a 1-year, randomized, double-blind, pla-
cebo-controlled, multicenter trial (Fig. 1). The target popula-
tion consists of four cohorts (n = 15 per cohort), stratified by
gender and age: males and females 15–17 years and males and
females 12–14 years. Following double-blind 1:1 randomiza-
tion, eligible subjects will receive either tolvaptan, adminis-
tered as 7.5-, 15-, and 30-mg immediate-release tablets, or
matching placebo tablets for up to 12 months. Tolvaptan and
placebo will be administered every day as split-dose regimens,
with the first dose taken upon waking and the second taken 8–
9 h later. Each dose will be administered with a recommended
240 mL of water consumed within a 1-h period. Subjects are
additionally encouraged to drink plain water per thirst
throughout the day and one to two glasses of water before
bedtime to help maintain proper hydration status.
Starting doses are based on weight. After 1 week, subjects
who tolerate their initial dose will up-titrate once, as noted in
SCREENING
Day –30 to –1 
TREATMENT PERIOD
Day 1 of Month 1 to end of Month 12
MONTH 12 VISIT
Complete Phase A and
continue to Phase B
Baseline
(1:1 Randomization)
Treatment Group
Day 1 to Month 12 (Up to 50 subjects)
Split-dose, based on weight
≥20 to 45 kg, 15/7.5 mg
>45 to 75 kg, 30/15 mg
>75 kg, 45/15 mg
Week 1
Up-titration
Placebo Group
Day 1 to Month 12 (up to 50 subjects)
Matching placebo, based on weight
Population:
Up to
100 subjects
aged 4 to
17 years
with ADPKD
Visits at Week 1, Month 1, Month 6, and Month 12.
Dispensing visits at Months 3, 9; monthly safety laboratory assessments.
Age Cohortsa: 
15 female subjects
ages 12 to 14 years,
inclusive
15 female subjects
ages 15 to 17 years,
inclusive
15 male subjects
ages 12 to 14 years,
inclusive
15 male subjects
ages 15 to 17 years,
inclusive
 
•
•
•
•
aSubjects between the ages of 4 and 11 are eligible for the trial but are not included in the age cohorts.
ADPKD, autosomal dominant polycystic kidney disease.
Fig. 1 Overall study design of phase A (randomized, double-blind).
aSubjects between the ages of 4 and 11 are eligible for the trial but are
not included in the age cohorts. ADPKD, autosomal dominant polycystic
kidney disease
Table 2 Tolvaptan weight-based dosing
Body weight Starting dose regimen Up-titrated dose regimen
≥ 20 kg to < 45 kg 15/7.5 mg tolvaptan or matching placebo 30/15 mg
≥ 45 kg to ≤ 75 kg 30/15 mg tolvaptan or matching placebo 45/15 mg
> 75 kg 45/15 mg tolvaptan or matching placebo 60/30 mg
Eur J Pediatr
Table 2. Subjects may down-titrate at any time in order to
determine the range of tolerated doses.
Phase B Phase B is a 2-year, open-label extension in up to 100
subjects aged 4–17 years who completed phase A on treat-
ment, are willing to continue in the study, and do not have any
adverse events (AEs) requiring study drug discontinuation
(Fig. 2)..
Efficacy and pharmacodynamic assessments
Phase A In phase A, spot urine osmolality and spot urine
specific gravity (co-primary endpoints) will be assessed at
baseline, week 1, and month 1. Serum creatinine will be
assessed at all visits, and serum sodium will be assessed at
all visits until month 11. The number of daytime and nighttime
voids will be recorded at week 1, month 1, month 6, and
month 12, and 24-h fluid balance will be evaluated at week 1.
Subjects 12–17 years of age will have their kidneys
scanned by MRI according to published standards [19] at
screening and month 12. All subjects will have renal pelvic
measurements by ultrasound at screening, month 1, and
month 12. Subsequent measurement of kidney dimensions
and evaluation of height-adjusted TKV will be performed at
a central laboratory by individuals blinded to treatment assign-
ment. As treatment effects on TKVor kidney function may be
difficult to discern in a pediatric population with early-stage
disease, pharmacodynamic parameters were considered the
most appropriate co-primary endpoints for this study.
Percent change from baseline to month 12 in height-adjusted
TKV was designated as the key secondary endpoint. All pri-
mary, secondary, and exploratory endpoints of the trial, for
both the 12–17- and the 4–11-year-old age groups, are listed
in Table 3.
Phase B In phase B, serum creatinine and serum sodium
assessments will occur at all visits until month 24. Twenty-
four-hour fluid balance will be evaluated at week 1. MRI
scans of the kidney will occur at month 12 and month 24.
Renal pelvic measurements by ultrasound will occur at
month 1 and month 12.
Pharmacokinetic assessments
During phase A only, sparse PK blood samples will be col-
lected from all subjects at week 1, month 1, month 6, and
month 12 for determination of steady-state concentrations of
plasma tolvaptan and metabolites.
In addition, after at least 1 month on treatment during phase
A, a subset of 20 consenting subjects in the 12–17-year-old
age group (10 on tolvaptan and 10 on placebo) will undergo
dense PK and PD sampling for 24 h following the schedule
and procedures described by Shoaf et al. [16]. The blind in
phase Awill be maintained in this dense PK subpopulation via
an Interactive Response System [13].
Subject-reported outcome assessments
Subject-reported outcomes are assessed using generic pediat-
ric quality-of-life questionnaires and information relevant to
MONTH 12 VISIT
Baseline for Phase B
TREATMENT PERIOD
Phase B Month 1 to Month 24
(Month 13 to Month 36 of overall trial)
FOLLOW-UP PERIOD
Phase B Months 1 to 24 (all subjects)
Based on weight
Split-dose, based on weight
≥20 to 45 kg, 15/7.5 mg
>45 to 75 kg, 30/15 mg
>75 kg, 45/15 mg
Rollover from Phase A to
Baseline Phase B
(Phase A/Month 12 = Baseline
Phase B)
Week 1
Up-titration
Population:
Subjects who
completed
Phase A on 
treatment and 
qualify for 
Phase B
Up to
100 eligible
subjects
• Visits on Week 1, Month 1, Month 6, Month 12,
   Month 18, and Month 24.
• Dispensing visits every 3 months, monthly 
   safety laboratory assessments.
7-day follow-up clinic visit
14-day follow-up telephone call
Fig. 2 Overall study design of phase B (open-label extension)
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the medical, social, and economic consequences of new and
ongoing ADPKD-related morbidities.
Safety assessments
Safety is assessed throughout the study by AE assessments,
clinical laboratory results, physical examination, vital signs,
and 12-lead electrocardiogram. At each study visit, the inves-
tigator elicits AEs with a nonleading question, and all AEs
reported by a subject must be recorded. Subjects in this study
will be tested for alanine aminotransferase (ALT), aspartate
aminotransferase (AST), alkaline phosphatase (ALP), and to-
tal bilirubin (BT) at screening/baseline and for ALT and AST
at week 1 and every month for the duration of the study. The
appearance of any suspicious symptom or sign in the investi-
gator’s clinical judgment (a liver function test 2 × upper limit
of normal [ULN] is generally accepted as a clinically signifi-
cant occurrence across various medical disciplines) will trig-
ger prompt re-testing, i.e., within 48–72 h. If significant ab-
normalities in transaminases and/or bilirubin are confirmed,
other testing to fully evaluate the likely proximate cause will
be undertaken, with the option of consulting local hepatic
Table 3 Endpoints of the study
Co-primary endpoints (phase A)
• Change from baseline in spot urine osmolality (premorning dose) after 1 week of daily dosing
• Change from baseline in specific gravity (premorning dose) after 1 week of daily dosing
Key secondary endpoint
• Percent change in htTKV from phase A baseline to month 12, as measured by MRI
Other secondary endpoints
• 24-h fluid balance prior to week 1 in phase A
• Change from baseline in renal function (eGFR by Schwartz formula [15]) at each clinic visit (week 1, month 1, month 6, and month 12 in phase A)
• Change from baseline in renal function (eGFR by Schwartz formula) at each clinic visit (week 1, month 1, month 6, month 12, month 18, and month
24 in phase B)
• Percent change in htTKVas measured by MRI from phase B baseline to phase B month 12
• Percent change in htTKVas measured by MRI from phase B baseline to phase B month 24
• Pharmacodynamic endpoints of urine volume (including 24-h fluid volume), fluid intake and fluid balance, sodium, creatinine, and free water
clearance during dense PK sampling (after at least 1 month on study drug)
• Proportions of each Tanner stage by gender and age compared to normative populations at baseline, month 6, and month 12 during the
placebo-controlled phase (phase A), and every 6 months during the open-label extension phase (phase B)
• Description of changes from baseline percentiles for height and weight by gender and age at baseline, month 6, and month 12 during the
placebo-controlled phase (phase A), and every 6 months during the open-label extension phase (phase B)
• Safety variables (changes from baseline in creatinine, vital signs, laboratory values including liver function tests, rate of aquaretic adverse events) in
placebo and tolvaptan
Exploratory endpoints
• Percent change in htTKVas measured by MRI from phase A baseline to phase B month 24
• Change from phase A baseline in spot urine osmolality (premorning dose) and specific gravity (premorning dose) after 1 month (phase A only)
• Time to discontinuation due to any reasons in phase A and phase B
• Tolvaptan maximum (peak) plasma concentration (Cmax), minimum plasma concentration (Cmin), time to Cmax (tmax), and area under the
concentration-time curve from time zero to 24 h (AUC0–24 h) following dense PK sampling
• PK sampling for separate population analysis
• Tolvaptan metabolite concentrations from dense sampling
• Generic pediatric quality of life assessments
• Daytime and nighttime void collection
Endpoints for subjects < 12 years who have ultrasound assessments
• Percent change in htTKVas measured by ultrasound from phase A baseline to phase A month 12
• Percent change in htTKVas measured by ultrasound from phase A baseline to phase B month 24
• Percent change in htTKVas measured by ultrasound from phase B baseline to phase B month 24
• Percent change in htTKVas measured by ultrasound from phase B baseline to phase B month 12
eGFR estimated glomerular filtration rate, htTKV height-adjusted total kidney volume, MRI magnetic resonance imaging, PK pharmacokinetic
Eur J Pediatr
experts for interpretation and guidance. In addition, a hepatic
adjudication committee has been convened for the purpose of
oversight of hepatic events.
Liver transaminase or bilirubin levels reaching or exceed-
ing 2 × ULN that have an uncertain or rapidly increasing tra-
jectory will prompt at least temporary interruption of
tolvaptan. Following interruption, tolvaptan will not be re-
sumed until monitoring indicates abnormalities have resolved,
are stable, or are not rapidly increasing, and then only with an
increased frequency of monitoring (e.g., once weekly until
returning to monthly monitoring at the discretion of the inves-
tigator) and if deemed appropriate in the clinical judgment of
the investigator. A subject will be discontinued from the study
on confirmation of any of the following criteria: ALT or AST
≥ 8 × ULN; ALT or AST ≥ 5 × ULN for more than 2 weeks;
ALT or AST ≥ 3 × ULN and either BT ≥ 2 × ULN or interna-
tional normalized ratio > 5; and ALT or AST ≥ 3 × ULN with
appearance of fatigue, nausea, vomiting, right upper quadrant
pain or tenderness, fever, rash, and/or eosinophilia (> 5%) and
signs of jaundice.
Statistics
Phase A will have two co-primary endpoints: change from
baseline in spot urine osmolality and specific gravity
(premorning dose) after 1 week of daily dosing. For the pri-
mary endpoint analysis, a sample size of at least 60 subjects
aged 12–17 years inclusive is expected. Since data will be
summarized using descriptive statistics and are aimed at test-
ing safety and tolerability, no formal power calculations were
undertaken.
Efficacy assessments will be conducted on the full analysis
set, defined as subjects who have been randomized to a treat-
ment group, have received at least one dose of study drug, and
have both a phase A baseline and at least one post-baseline
efficacy evaluation. Subgroup analyses of the primary and key
secondary endpoints will be performed to examine differences
in treatment response based on phase A baseline status (e.g.,
gender, age stratum). For all secondary endpoints, descriptive
statistics by visit will be presented.
Safety analyses will be conducted on all subjects who re-
ceived one dose of study drug. Summary statistics of changes
from phase A and phase B baseline will be provided for safety
variables based on all available data.
Discussion
The purpose of the study described here is to assess the safety,
tolerability, PD, PK, and efficacy of tolvaptan in children with
ADPKD. As this will be the first study to assess tolvaptan in
pediatric subjects with ADPKD, a number of features associ-
ated with the study population have been considered and
addressed. For example, it is expected that very few, if any,
of the screened participants will present with disease-specific
symptoms, and formal diagnostic criteria for ADPKD so early
in disease progression have yet to be developed. To circum-
vent this issue, an advisory panel of experts was convened to
develop screening standards. The consensus opinion was that
family history/genetics, cyst number as assessed by MRI (or
ultrasound in younger subjects), and progression of disease
that would warrant treatment are together the most reasonable
approach to diagnose early disease. Therefore, to be eligible
for enrollment, subjects must have a family history and/or
genetic criteria for ADPKD and ≥ 10 renal cysts, each mea-
suring ≥ 0.5 cm on MRI; subjects under the age of 12 years
must have ≥ 4 cysts, each measuring ≥ 1 cm on ultrasound.
The early stage of polycystic kidney disease in the pediatric
study population also complicates efficacy assessments. Post
hoc analyses of TEMPO 3:4 showed that the beneficial treat-
ment effects of tolvaptan on TKV and eGFR were similar
across chronic kidney disease (CKD) stages, including among
subjects early in disease progression (CKD 1) [20]. Although
clinically significant, the absolute changes in TKV growth and
eGFR decline versus placebo were nonetheless relatively
small across CKD stages and could be particularly difficult
to detect in pediatric subjects. Given that a large sample size
and long follow-up would likely be necessary to discern treat-
ment effects on TKV growth and eGFR decline in a pediatric
population, the study steering committee and regulatory au-
thorities agreed that pharmacodynamic effects would be more
practicable and informative primary study endpoints in a first
trial of tolvaptan for the treatment of pediatric ADPKD.
Accordingly, the co-primary endpoints are change from base-
line in spot urine osmolality and in urine specific gravity.
These endpoints will assess whether tolvaptan acts in the same
way in children/adolescents as it does in adults, which has not
been examined before. Results from these analyses should
inform the choice of assessments in future pediatric trials.
In adults, optimal ADPKD treatment requires constant
24-h inhibition of the V2 receptor, and patients are thus typ-
ically encouraged to take maximally tolerated doses. Adults
receive a split-dosing regimen to maintain suppression of
vasopressin action across 24 h, consisting of a higher dose
early in the day, followed by a lower dose approximately 8–
9 h later. The primary tolerability concern with tolvaptan
dosing is excretion of solute-free water, or aquaresis, which
manifests as polyuria (production of large volumes of dilute
urine), polydipsia (excess thirst and drinking), nocturia (need
to wake up to urinate at night), and pollakiuria (abnormally
frequent urination) [19]. Post hoc analyses of the TEMPO 3:4
study population showed that aquaretic AEs resulting in
tolvaptan discontinuation were more likely in subjects with
higher baseline renal function [4]. Furthermore, sensitivity to
aquaretic effects appeared to be highest during initial titration
of the drug [4].
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Combined, the adult data on aquaresis suggest that the
current study’s pediatric ADPKD population, with its high
renal clearance capacity and younger age demographic, could
be especially sensitive to aquaretic AEs, particularly early
during titration. Subjects within each cohort will therefore
initiate treatment at a weight-adjusted split starting dose that
is no greater than 67% of the maximal weight-adjusted
starting dose for the adult subjects in TEMPO 3:4. This low
starting dose will be administered for 1 week to allow accli-
mation to the excess diuresis commonly associated with
tolvaptan and, hopefully, to avoid potential problems with
aquaretic AEs early in titration. Only after 1 week at the
starting dose, if tolerated, will the dosage be up-titrated once
to the weight-adjusted starting dose used in TEMPO 3:4. As is
the case with adult dosing, participants will receive a higher
dose early in the day, followed by a lower dose administered
approximately 8–9 h later, which produces maximal inhibition
on waking and a gradual fall-off of effect during the night,
when frequent urination would lead to interruption of sleep.
The most notable safety issue with tolvaptan in adult
ADPKD studies was the potential for idiosyncratic hepatic
toxicity [22]. To mitigate this risk, the frequency of liver func-
tion testing was increased from once every 4 months in
TEMPO 3:4 to once monthly in REPRISE [22] .
Accordingly, subjects in the current pediatric study will be
tested for ALT/AST, ALP, and BT during screening and for
ALT/AST at week 1 and monthly during the entire trial.
Evidence of liver damage will be assessed by the local physi-
cian, an independent hepatic adjudication committee, and an
independent data monitoring committee. In addition, stringent
drug interruption rules will be employed to ensure rapid re-
sponse to any potential hepatic signals.
The current study has some potential limitations resulting
from its design. First, the dramatic difference in aquaretic
effect between tolvaptan and placebo may lead the subject
and/or investigator to perceive treatment assignment. The pre-
scription of additional fluids to subjects during study drug
administration may serve to confound this effect, and it should
be noted that the pharmacodynamic and efficacy endpoints are
objective and unlikely to be affected by the participant’s per-
ceptions. Second, the study inclusion criteria relating to
ADPKD diagnosis and cyst burden are largely opinion-based,
and their predictive value for early disease progression re-
mains unknown. The criteria are justifiable, however, given
study data indicating that cyst burden correlates with the pres-
ence of hypertension in pediatric ADPKD patients, and that
hypertension is predictive of rapid disease progression in this
population [2, 6, 12]. Finally, tolerability of tolvaptan in a
population that still has good renal function may be dose lim-
iting or could cause early tolvaptan discontinuation.
Nonetheless, the current study is expected to provide valuable
information on the safety, tolerability, PD, PK, and efficacy of
tolvaptan in pediatric patients with ADPKD and potentially
inform the design of trials intended to assess therapeutic effi-
cacy in this population.
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